3 completed, 1 withdrawn. 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Stage IIA Melanoma: new trials by email Literature Review of Stage IIA Melanoma trials Research Report on Stage IIA Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis - Stage IB Melanoma, Stage IIA Melanoma | Phase 3 | Withdrawn | Jonsson Comprehensive Cancer Center | 2011-08-05 | 2020-07-27 | |
| Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery saracatinib - Recurrent Melanoma, Stage IIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2006-07-01 | 2014-05-21 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis - Recurrent Melanoma, Stage IA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 1999-04-01 | 2017-02-20 |
Melanoma (4)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Skin Diseases (4) · Skin Neoplasms (4) · Skin and Connective Tissue Diseases (4)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · MART-1 Antigen (1) · S 28463 (1) · Saline Solution, Hypertonic (1) · Sentinel Lymph Node Biopsy (1) · montanide ISA 51 (1) · resiquimod (1) · saracatinib (1) · sargramostim (1)
National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1)
United States (4)
Richard Essner (1) · Svetomir Markovic, M.D., Ph.D. (1) · Thomas Gajewski (1) · Walter J. Urba, MD, PhD (1)
N01CM62201 (1), R01CA120228 (1), R21CA082614 (1)